8 results about "Atovaquone" patented technology

The disclosure relates to the use of atovaquone or a salt thereof, and, optionally, proguanil or a salt thereof, for the treatment of various human diseases and conditions, including gastrointestinal disorders and, in particular, those associated with inflammation, such as inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The invention discloses a phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting. The phototherapy nano-drug is ATO / CR nano-particles formed by self-assembling a compound CR and atorvaquone under the action of distearoyl phosphatidyl ethanolamine-polyethylene glycol; the structure of the compound CR is shown as a formula I in the specification. The invention discloses an application of the phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting in preparation of drugs for treating tumors. The phototherapy nano-drug can target mitochondria and STAT3 protein in tumor cells through ATO, and can also passively target tumor sites through the high-permeability long-retention effect of nano-particles, so that more nano-therapeutic agents are enriched around tumors, and the curative effect is improved. The phototherapy nano-drug provided by the invention has good photothermal performance, can effectively enhance the PTT effect of gastric cancer, and exerts the tumor synergistic treatment ability by promoting cell apoptosis, inhibiting angiogenesis and hindering the cell cycle.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a compound Atovaquone for treating cardiomyopathy, and the cardiomyopathy refers to all diseases causing myocardial structure and dysfunction, including secondary cardiac hypertrophy / heart failure and primary hypertrophic cardiomyopathy. The compound can be prepared into granules, capsules, powder, tablets and injection preparations together with another active ingredient which is different from the compound shown in the formula I and has the functions of enhancing the heart function, expanding peripheral blood vessels, reducing myocardial oxygen consumption and the like, and pharmaceutically acceptable auxiliary materials are added.

The invention provides an application of a drug micromolecule Atovaquone in preparation of a drug for resisting a cochlea virus, belongs to the field of drug preparation, provides a new application direction of the Atovaquone and a new direction of preparing the drug for resisting the cochlea virus by applying the drug micromolecule Atovaquone in preparation of the drug for resisting the cochlea virus, and provides a new application field of the Atovaquone and a new application field of the drug for resisting the cochlea virus and a new application field of the drug for resisting the cochlea virus and a new application field of the drug for resisting the cochlea virus and a new application field of the drug for resisting the cochlea virus and a new application field of the drug for resisting the cochlea virus. And a new thought is provided for prevention and treatment of the Dazaka virus.

The present invention discloses a self-assembling nanophotosensitizer, preparation method, and application. The nanophotosensitizer is composed of TPP-Ppa@ATO@CAT@RGD-PEG-BSA, which is primarily self-assembled from the mitochondrial-targeting porphyrin TPP-Ppa, atovaquone (ATO), catalase (CAT), and RGD-PEG-BSA with active cell-targeting function. This photosensitizer can enhance the effect of photodynamic therapy through dual targeting and dual pathways to increase oxygen. It can also induce an immunogenic death effect through photodynamic therapy, and in combination with anti-PD-L1 antibodies, achieve step-by-step enhanced photodynamic immunotherapy for breast cancer.